AbbVie Inc. vs Qualcomm Inc.: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Qualcomm Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Qualcomm Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Qualcomm Inc. is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $44.3B for Qualcomm Inc., while their respective market capitalizations stand at $465.8B and $208.0B. Both AbbVie Inc. and Qualcomm Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

AbbVie Inc.: AbbVie became an independent public biopharmaceutical company in January 2013 after Abbott Laboratories separated its research-based pharmaceutical business. Humira initially dominated its portfolio. AbbVie has since added Pharmacyclics, Allergan, ImmunoGen, and Cerevel and now reports major portfolios in immunology, neuroscience, oncology, and aesthetics.

Qualcomm Inc.: Qualcomm Incorporated (NASDAQ: QCOM) is one of the world's largest fabless semiconductor companies and a leading holder of cellular patents. Founded in San Diego in 1985, it helped commercialize CDMA, the technology behind 3G networks, and today supplies Snapdragon platforms to Android phone makers such as Samsung and Xiaomi, plus chips for cars, PCs, XR headsets and industrial devices. It had about 52,000 employees in FY2025 and a market value of roughly $208B in late September 2026.

AbbVie Inc. and Qualcomm Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Qualcomm Inc..

AbbVie Inc. business model: AbbVie earns revenue from global sales of prescription medicines and Allergan Aesthetics products. Its FY2025 portfolios were led by immunology at $30.406 billion, neuroscience at $10.767 billion, oncology at $6.655 billion, and aesthetics at $4.860 billion. The company funds internal research and supplements its pipeline through licensing and acquisitions.

Qualcomm Inc. business model: Qualcomm earns money in two ways. QCT (Qualcomm CDMA Technologies) designs Snapdragon systems-on-chip, modems, RF front-end and Wi-Fi/Bluetooth chips and sells them to handset, automotive, PC and IoT customers; manufacturing is outsourced to foundries such as TSMC and Samsung. QCT produced $38.367B of FY2025 revenue, including $27.793B from handsets, $6.617B from IoT and $3.957B from automotive. QTL (Qualcomm Technology Licensing) licenses Qualcomm's standard-essential and other wireless patents to device makers for royalties based on device prices. QTL is much smaller than QCT by revenue but carries far higher margins (a 69% EBT margin in Q3 FY2026), so it contributes an outsized share of profit.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Qualcomm Inc..

AbbVie Inc. competitive advantage: AbbVie's scale rests on its immunology portfolio, specialist commercial infrastructure, approved products across several therapeutic areas, and acquired oncology, neuroscience, and aesthetics assets. Those strengths are offset by patent-expiration, clinical-development, safety, reimbursement, and pricing risks described in its Form 10-K.

Qualcomm Inc. competitive advantage: Qualcomm's edge comes from pairing leading cellular modem and RF engineering with one of the largest portfolios of standard-essential wireless patents. That combination lets it sell integrated Snapdragon platforms (CPU, GPU, NPU, modem and RF) while still collecting royalties on phones that use rival chips. Its custom Oryon CPU cores, from the 2021 Nuvia deal, now run in both flagship phone and Windows PC chips. The advantage is not absolute: Apple began shipping its own C1 modem in 2025 and MediaTek competes hard in Android.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Qualcomm Inc. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

Qualcomm Inc. growth strategy: Qualcomm's growth plan is to reuse Snapdragon's low-power compute, connectivity and AI engines outside phones. Automotive is the clearest win so far, with the Snapdragon Digital Chassis growing from $2.9B in FY2024 to $3.957B in FY2025 and $1.6B in Q3 FY2026 alone. Snapdragon X chips target Windows Copilot+ laptops. Industrial IoT and robotics carry a design-win pipeline above $7B. The newest bet is the data center: Qualcomm bought Alphawave Semi (completed December 2025) for high-speed connectivity, agreed to buy AI software firm Modular for about $3.9B in 2026, and is building AI accelerators, server CPUs and custom silicon for two hyperscalers.

A closer look at the financial trajectory of AbbVie Inc. and Qualcomm Inc. rounds out the comparison.

AbbVie Inc.: AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets.

Qualcomm Inc.: Qualcomm's revenue has swung with the smartphone cycle: $44.2B in FY2022, $35.8B in FY2023, $39.0B in FY2024 and a record $44.284B in FY2025. FY2025 operating income was $12.355B, but GAAP net income dropped to $5.541B because of a large non-cash income tax charge booked in the September 2025 quarter. FY2026 has been tougher on the top line. Q2 revenue was $10.599B, and Q3 revenue fell 4% year over year to $9.9B with GAAP EPS of $1.87 and non-GAAP EPS of $2.21, as higher memory costs squeezed handset demand. QTL revenue was $1.3B in Q3. Qualcomm returned $2.3B to shareholders that quarter and guided Q4 FY2026 revenue to $9.7B-$10.5B.